title: A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
abstract: BACKGROUND
  In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuberculosis is high. We conducted a trial with a 2-by-2 factorial design to assess the benefits of early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-infected adults with high CD4+ cell counts in Ivory Coast.
  
  
  METHODS
  We included participants who had HIV type 1 infection and a CD4+ count of less than 800 cells per cubic millimeter and who met no criteria for starting ART according to World Health Organization (WHO) guidelines. Participants were randomly assigned to one of four treatment groups: deferred ART (ART initiation according to WHO criteria), deferred ART plus IPT, early ART (immediate ART initiation), or early ART plus IPT. The primary end point was a composite of diseases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defining cancer, non-AIDS-defining invasive bacterial disease, or death from any cause at 30 months. We used Cox proportional models to compare outcomes between the deferred-ART and early-ART strategies and between the IPT and no-IPT strategies.
  
  
  RESULTS
  A total of 2056 patients (41% with a baseline CD4+ count of ≥500 cells per cubic millimeter) were followed for 4757 patient-years. A total of 204 primary end-point events were observed (3.8 events per 100 person-years; 95% confidence interval [CI], 3.3 to 4.4), including 68 in patients with a baseline CD4+ count of at least 500 cells per cubic millimeter (3.2 events per 100 person-years; 95% CI, 2.4 to 4.0). Tuberculosis and invasive bacterial diseases accounted for 42% and 27% of primary end-point events, respectively. The risk of death or severe HIV-related illness was lower with early ART than with deferred ART (adjusted hazard ratio, 0.56; 95% CI, 0.41 to 0.76; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.56; 95% CI, 0.33 to 0.94) and lower with IPT than with no IPT (adjusted hazard ratio, 0.65; 95% CI, 0.48 to 0.88; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.61; 95% CI, 0.36 to 1.01). The 30-month probability of grade 3 or 4 adverse events did not differ significantly among the strategies.
  
  
  CONCLUSIONS
  In this African country, immediate ART and 6 months of IPT independently led to lower rates of severe illness than did deferred ART and no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter. (Funded by the French National Agency for Research on AIDS and Viral Hepatitis; TEMPRANO ANRS 12136 ClinicalTrials.gov number, NCT00495651.).
authors.forename: Christine
authors.initials: C
authors.lastname: Danel
authors.forename: Raoul
authors.initials: R
authors.lastname: Moh
authors.forename: Delphine
authors.initials: D
authors.lastname: Gabillard
authors.forename: Anani
authors.initials: A
authors.lastname: Badje
authors.forename: Jérôme
authors.initials: J
authors.lastname: Le Carrou
authors.forename: Timothée
authors.initials: T
authors.lastname: Ouassa
authors.forename: Eric
authors.initials: E
authors.lastname: Ouattara
authors.forename: Amani
authors.initials: A
authors.lastname: Anzian
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Ntakpé
authors.forename: Albert
authors.initials: A
authors.lastname: Minga
authors.forename: Gérard M
authors.initials: GM
authors.lastname: Kouame
authors.forename: Franck
authors.initials: F
authors.lastname: Bouhoussou
authors.forename: Arlette
authors.initials: A
authors.lastname: Emieme
authors.forename: Antoine
authors.initials: A
authors.lastname: Kouamé
authors.forename: André
authors.initials: A
authors.lastname: Inwoley
authors.forename: Thomas-d'Aquin
authors.initials: TD
authors.lastname: Toni
authors.forename: Hugues
authors.initials: H
authors.lastname: Ahiboh
authors.forename: Mathieu
authors.initials: M
authors.lastname: Kabran
authors.forename: Cyprien
authors.initials: C
authors.lastname: Rabe
authors.forename: Baba
authors.initials: B
authors.lastname: Sidibé
authors.forename: Gustave
authors.initials: G
authors.lastname: Nzunetu
authors.forename: Romuald
authors.initials: R
authors.lastname: Konan
authors.forename: Joachim
authors.initials: J
authors.lastname: Gnokoro
authors.forename: Patrice
authors.initials: P
authors.lastname: Gouesse
authors.forename: Eugène
authors.initials: E
authors.lastname: Messou
authors.forename: Lambert
authors.initials: L
authors.lastname: Dohoun
authors.forename: Synali
authors.initials: S
authors.lastname: Kamagate
authors.forename: Abo
authors.initials: A
authors.lastname: Yao
authors.forename: Solange
authors.initials: S
authors.lastname: Amon
authors.forename: Amadou-Barenson
authors.initials: AB
authors.lastname: Kouame
authors.forename: Aboli
authors.initials: A
authors.lastname: Koua
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Kouamé
authors.forename: Yao
authors.initials: Y
authors.lastname: Ndri
authors.forename: Olivier
authors.initials: O
authors.lastname: Ba-Gomis
authors.forename: Marcelle
authors.initials: M
authors.lastname: Daligou
authors.forename: Simplice
authors.initials: S
authors.lastname: Ackoundzé
authors.forename: Denise
authors.initials: D
authors.lastname: Hawerlander
authors.forename: Alex
authors.initials: A
authors.lastname: Ani
authors.forename: Fassery
authors.initials: F
authors.lastname: Dembélé
authors.forename: Fatoumata
authors.initials: F
authors.lastname: Koné
authors.forename: Calixte
authors.initials: C
authors.lastname: Guéhi
authors.forename: Constance
authors.initials: C
authors.lastname: Kanga
authors.forename: Serge
authors.initials: S
authors.lastname: Koule
authors.forename: Jonas
authors.initials: J
authors.lastname: Séri
authors.forename: Mykayila
authors.initials: M
authors.lastname: Oyebi
authors.forename: Nathalie
authors.initials: N
authors.lastname: Mbakop
authors.forename: Olewole
authors.initials: O
authors.lastname: Makaila
authors.forename: Carole
authors.initials: C
authors.lastname: Babatunde
authors.forename: Nathanael
authors.initials: N
authors.lastname: Babatounde
authors.forename: Gisèle
authors.initials: G
authors.lastname: Bleoué
authors.forename: Mireille
authors.initials: M
authors.lastname: Tchoutedjem
authors.forename: Alain-Claude
authors.initials: AC
authors.lastname: Kouadio
authors.forename: Ghislaine
authors.initials: G
authors.lastname: Sena
authors.forename: Sahinou-Yediga
authors.initials: SY
authors.lastname: Yededji
authors.forename: Rodrigue
authors.initials: R
authors.lastname: Assi
authors.forename: Alima
authors.initials: A
authors.lastname: Bakayoko
authors.forename: Alassane
authors.initials: A
authors.lastname: Mahassadi
authors.forename: Alain
authors.initials: A
authors.lastname: Attia
authors.forename: Armel
authors.initials: A
authors.lastname: Oussou
authors.forename: Max
authors.initials: M
authors.lastname: Mobio
authors.forename: Doféré
authors.initials: D
authors.lastname: Bamba
authors.forename: Mesmin
authors.initials: M
authors.lastname: Koman
authors.forename: Apollinaire
authors.initials: A
authors.lastname: Horo
authors.forename: Nina
authors.initials: N
authors.lastname: Deschamps
authors.forename: Henri
authors.initials: H
authors.lastname: Chenal
authors.forename: Madeleine
authors.initials: M
authors.lastname: Sassan-Morokro
authors.forename: Seidou
authors.initials: S
authors.lastname: Konate
authors.forename: Kakou
authors.initials: K
authors.lastname: Aka
authors.forename: Eba
authors.initials: E
authors.lastname: Aoussi
authors.forename: Valérie
authors.initials: V
authors.lastname: Journot
authors.forename: Célestin
authors.initials: C
authors.lastname: Nchot
authors.forename: Sophie
authors.initials: S
authors.lastname: Karcher
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Chaix
authors.forename: Christine
authors.initials: C
authors.lastname: Rouzioux
authors.forename: Papa-Salif
authors.initials: PS
authors.lastname: Sow
authors.forename: Christian
authors.initials: C
authors.lastname: Perronne
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Girard
authors.forename: Hervé
authors.initials: H
authors.lastname: Menan
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Bissagnene
authors.forename: Auguste
authors.initials: A
authors.lastname: Kadio
authors.forename: Virginie
authors.initials: V
authors.lastname: Ettiegne-Traore
authors.forename: Corinne
authors.initials: C
authors.lastname: Moh-Semdé
authors.forename: Abo
authors.initials: A
authors.lastname: Kouame
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Massumbuko
authors.forename: Geneviève
authors.initials: G
authors.lastname: Chêne
authors.forename: Mireille
authors.initials: M
authors.lastname: Dosso
authors.forename: Serge K
authors.initials: SK
authors.lastname: Domoua
authors.forename: Thérèse
authors.initials: T
authors.lastname: N'Dri-Yoman
authors.forename: Roger
authors.initials: R
authors.lastname: Salamon
authors.forename: Serge P
authors.initials: SP
authors.lastname: Eholié
authors.forename: Xavier
authors.initials: X
authors.lastname: Anglaret
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D058070:Asymptomatic Diseases; D018791:CD4 Lymphocyte Count; D007560:Cote d'Ivoire; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D061665:Time-to-Treatment; D014376:Tuberculosis / Q000517:prevention & control*; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D000995:Antitubercular Agents; D012367:RNA, Viral; D007538:Isoniazid